Cresset releases Flare V12 to cut synthesis and testing cycles with faster, more flexible FEP
Cresset has released Flare V12, a new version of its computer-aided drug design (CADD) solution for the discovery, design and optimization of small molecules. Flare V12 is focussed on improving access to Free Energy Perturbation (FEP) in drug discovery.
AI unlocks unparalleled efficiency gains in Flare™ V11, Cresset’s leading software solution for digital molecular discovery
10 December 2025 – Cambridge, UK; Cresset, a leading provider of digital molecular discovery solutions that combine cutting-edge science with AI/ML, announces the latest release of their flagship CADD platform, Flare. New AI features are complemented by significant advances in existing capabilities such as Flare FEP (Free Energy Perturbation).
Cresset releases Flare™ V10, the latest update to its agile ligand and structure-based drug design platform, featuring significant scientific enhancements for computational and medicinal chemists
12th February 2025 – Cambridge, UK – Cresset, a leading provider of integrated in silico solutions for small molecule drug discovery announces the release of its Flare platform V10, bringing enhanced scientific features for both computational and medical chemists.
Cresset appoints new Non-Executive Director
Cresset, innovative provider of computational drug discovery and development solutions that accelerate research outcomes, have announced the appointment of Dale Curtis as Non-Executive Director.
Cresset® appoints new Chairman
Cambridge – Cresset, innovative provider of computational drug discovery and development solutions that accelerate research outcomes, have announced the appointment of David Newble as Group Chairman.
Cresset: Bionow Award for internationalisation
Cresset writes...thank you to Bionow and all the event sponsors for an excellent evening at the annual Bionow awards.
Are Free Energy Perturbation (FEP) methods suitable for your project?
Free Energy Perturbation (FEP) methods are a fast-evolving area of drug discovery, and Cresset Discovery’s dedicated team of expert modelers are establishing a rapidly growing portfolio of successfully completed FEP projects.
Cresset targets international growth with Innovate UK Scaleup Programme
October 18th, 2023, Cambridge, UK - Cresset, an innovative provider of solutions for computer-aided drug design (CADD), design-make-test-analyze (DMTA) efficiency, and drug discovery contract research has been accepted onto the
Cresset shares September 2023 news
Welcome to the September Cresset NewsletterOptimize your decision-making across the entire design-make-test-analyze (DMTA) cycle with this month's collection of CADD software features, expert scientific opinion, and first-class drug discovery research resources.
Streamline sharing of CADD data seamlessly to accelerate your drug design process
Introduction
The globalized outsourcing model of modern drug discovery is driving efficiencies across the Design-Make-Test-Analyze (DMTA) cycle.
Torx® Software announces global drug discovery collaboration with CDD Vault®
Cambridge, UK - 12th September 2023 - Torx® Software Limited announces a collaboration with CDD Vault to facilitate the seamless synthesis and registration of new compounds during the small-molecule drug discovery process.
Cresset Discovery shares insights on escaping fluorinated chemical space
Introduction
At Cresset Discovery the team endeavour to remain up to date with the changing development landscape, exploring new methods and techniques but also examining trends and problems that are approaching.
Skeletal editing and removing the gap between CADD/AIDD and synthesis
In the fields of peptide and protein synthesis, there is a very efficient translation between design and synthesis – this operates generally via the mechanism of DNA synthesis, and then various expression platforms or through direct synthesis routes at the amino acid level.
Latest updates from Cresset - August 2023 Newsletter
Welcome to the August Cresset NewsletterDiscover this month's latest CADD software news and molecular modeling expertise, all in support of enabling seamless collaboration and enhanced insights across the DMTA cycle.
Building QSAR models with RDKit Fingerprints and 2D descriptors in Flare™
Within Flare, the comprehensive software platform for ligand-based and structure-based drug design, users can build 3D Quantitative Structure-Activity Relationship (QSAR) models using 3D descriptors of electrostatic and shape.
Flare V7: What's new for ligand-based and structure-based drug designers?
Earlier this month, our Principal Application Scientists, Stuart Firth-Clark, and Nathan Kidley led an exclusive online webinar, focused on guiding attendees through the new structure-based functionality (such as GCNCMC in dynamics/FEP; ensemble covalent docking) and ligand-based functionality (s
Cresset's June 2023 Newsletter
Cresset are pleased to announce the release of Torx 2.0 and the Flare Python Cookbook V3.0, alongside a variety of new science in the latest Cresset monthly newsletter.
Cresset Creates New Vice President Role to Lead their Discovery CRO Business
Nick Foster appointed Vice President of Cresset Discovery CRO business
New ‘ready-to-use’ recipes in the Flare™ Python Cookbook enable chemists to quickly triage molecules and accelerate the drug design process
The Flare Python API gives full access to the scientific capabilities in Flare, enabling users to work more efficiently by creating their own workflows, automating common tasks, and expanding Flare with python modules an
Torx® 2.0 - Unique molecule life cycle platform released
Cambridge, UK - Torx® Software Limited, announces the release of Torx 2.0, extending the platform’s scientific reach and capabilities to deliver unrivalled seamless integration across the drug discovery Design-Make-Test-Analyze (DMTA) cycle.
Growing Peptides in Flare™
Therapeutic Peptides are a class of pharmaceutical agent composed of a series of well-ordered amino acids usually having the molecular weight between 500-5000 Da.1 The discovery of several lifesaving bioactive peptides like the 51-amino acid hormone insulin,2 and t
Cresset releases Flare™ V7
Flare™ is a comprehensive drug design platform that integrates the power of ligand and
Performing chemical modifications using the Library Enumerator in Flare™
Abstract
The correct assignment of the tautomeric and protonation states of ligands is critical for successful molecular modeling experiments in both ligand-based and structure-based design approaches, as it may have a significant effect on the shape and electrostatic properties of the
Cresset newsletter May 2023
Cresset's May newsletter shares exciting new CADD and DMTA software updates, new science, upcoming events, and job openings.